Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study

• Published in: Radiotherapy and oncology Vol. 200; p. 110479
• Main Authors: Beukema, Jannet C., Haveman, Jan-Willem, Langendijk, Johannes A., Oldehinkel, Edwin, van den Bergh, Alphons C.M., de Haan, Jacco J., van Melle, Joost P., van Luijk, Peter, Muijs, Christina T.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.11.2024
• ISSN: 0167-8140; 1879-0887; 1879-0887
• DOI: 10.1016/j.radonc.2024.110479

•Significant association of blood biomarkers and radiation DVH parameters in esophageal cancer.•Significant association of blood biomarkers and clinical events after CRT for esophageal cancer.•HS TNT and Pro BNP can be useful in radiotherapy prediction models for cardiac events. The aim of this study was to test the hypothesis that the levels of High Sensitive Troponin T (HS-TNT) and N-terminal Brain Natriuretic Peptide (NT-ProBNP) increase after radiation therapy in a dose dependent way and are predictive for clinical cardiac events. Blood samples during and after radiotherapy of 87 esophageal cancer patients were analysed regarding the course of HS-TNT and NT-ProBNP levels and their relationship with clinical toxicity endpoints and radiation dose volume parameters. HS-TNT values at the end of treatment correlated with the mean heart dose (p = 0.02), whereas the rise of NT-ProBNP correlated with the mean lung dose (p = 0.01). Furthermore, the course of both HS-TNT (p < 0.001) and NT-ProBNP (p < 0.01) levels were significantly different for patients who developed new cardiac events as opposed to those without new cardiac events. Significant correlations were found for both biomarkers with radiation dose and clinical toxicity endpoints after treatment. Therefore, these markers might be of additional value in NTCP models for cardiac events and might help us unravelling the mechanisms behind these toxicity endpoints.